NEW YORK (GenomeWeb) – OpGen lowered the price range on its planned initial public offering, resulting in a sharp drop in its anticipated net proceeds. 

In an amended prospectus filed with the US Securities and Exchange Commission on Thursday, the microbial genetics analysis firm said it anticipates offering 2.5 million units in its IPO at between $5.50 and $6.50 per unit, with net proceeds expected at about $12.6 million at the midpoint price of $6 per unit. Each unit consists of one share of OpGen's common stock and one warrant to purchase an additional share. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.

Jan
31
Sponsored by
Roche

This webinar highlights the use of single-cell genomics to identify distinct cell types and states associated with enhanced immunity.